EP2023874A4 - Methods for identifying agents and their use for the prevention of restenosis - Google Patents
Methods for identifying agents and their use for the prevention of restenosisInfo
- Publication number
- EP2023874A4 EP2023874A4 EP07809331A EP07809331A EP2023874A4 EP 2023874 A4 EP2023874 A4 EP 2023874A4 EP 07809331 A EP07809331 A EP 07809331A EP 07809331 A EP07809331 A EP 07809331A EP 2023874 A4 EP2023874 A4 EP 2023874A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- restenosis
- prevention
- methods
- identifying agents
- identifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81050806P | 2006-06-02 | 2006-06-02 | |
US93803107P | 2007-05-15 | 2007-05-15 | |
PCT/US2007/013230 WO2007143211A2 (en) | 2006-06-02 | 2007-06-04 | Methods for identifying agents and their use for the prevention of restenosis |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2023874A2 EP2023874A2 (en) | 2009-02-18 |
EP2023874A4 true EP2023874A4 (en) | 2009-07-08 |
Family
ID=38802134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07809331A Withdrawn EP2023874A4 (en) | 2006-06-02 | 2007-06-04 | Methods for identifying agents and their use for the prevention of restenosis |
Country Status (4)
Country | Link |
---|---|
US (2) | US8697387B2 (en) |
EP (1) | EP2023874A4 (en) |
JP (1) | JP2009542583A (en) |
WO (1) | WO2007143211A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2135078B1 (en) * | 2007-03-09 | 2013-08-21 | DiscoveRx Corporation | Methods for identifying agents and their use for the prevention or stabilization of fibrosis |
EP2152944A4 (en) | 2007-03-30 | 2010-12-01 | Bioseek Inc | Methods for classification of toxic agents and counteragents |
US8992601B2 (en) | 2009-05-20 | 2015-03-31 | 480 Biomedical, Inc. | Medical implants |
US9265633B2 (en) | 2009-05-20 | 2016-02-23 | 480 Biomedical, Inc. | Drug-eluting medical implants |
US20110319987A1 (en) | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
US8888840B2 (en) * | 2009-05-20 | 2014-11-18 | Boston Scientific Scimed, Inc. | Drug eluting medical implant |
US9309347B2 (en) | 2009-05-20 | 2016-04-12 | Biomedical, Inc. | Bioresorbable thermoset polyester/urethane elastomers |
CA3186201A1 (en) * | 2009-05-20 | 2010-11-25 | Lyra Therapeutics, Inc. | Self-expandable medical device comprising polymeric strands and coatings thereon |
US10265281B2 (en) | 2012-11-02 | 2019-04-23 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
JP2015035196A (en) * | 2012-11-03 | 2015-02-19 | 有限会社 ミクロデント | N calculating device |
EA039635B1 (en) * | 2012-11-05 | 2022-02-18 | Марри Энд Пул Энтерпрайзес, Лтд. | Treatment or prevention of cardiovascular events using a colchicine derivative |
PL2986280T3 (en) | 2013-04-16 | 2021-10-25 | Murray & Poole Enterprises, Ltd. | Sustained-release formulations of colchicine and methods of using same |
KR101778439B1 (en) | 2015-04-27 | 2017-09-14 | 울산대학교 산학협력단 | composition for improving immunity and anti-cancer activity comprising natural killer cell activator |
EP3405214B1 (en) * | 2016-01-22 | 2023-07-05 | Puyo, Carlos A. | Anti-neutrophil activity on innate immune response |
US11058690B2 (en) * | 2017-01-22 | 2021-07-13 | Beijing Weilanzhiyuan Medical Technology Co., Ltd. | Use of cytochrome bc1 complex inhibitor in preparing pharmaceutical composition |
GB201720320D0 (en) | 2017-12-06 | 2018-01-17 | Univ Of Sussex | Tissue repair |
KR20210062449A (en) * | 2019-11-21 | 2021-05-31 | 연세대학교 산학협력단 | Vascular leakage blocking effect of primaquine diphosphate and its targets usp1 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005093561A1 (en) * | 2004-02-27 | 2005-10-06 | Bioseek, Inc. | Biological dataset profiling of asthma and atopy |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3006812A (en) * | 1960-09-21 | 1961-10-31 | Lab Francais Chimiotherapie | N-desacetyl colchiceine for the treatment of gout |
US6004346A (en) | 1990-02-28 | 1999-12-21 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5498238A (en) | 1990-06-15 | 1996-03-12 | Cortrak Medical, Inc. | Simultaneous angioplasty and phoretic drug delivery |
US6060451A (en) | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
US5891108A (en) | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
GB9525620D0 (en) | 1995-12-15 | 1996-02-14 | Glaxo Group Ltd | Chemical compounds |
SE9600216D0 (en) | 1996-01-18 | 1996-01-18 | Hans Arne Hansson | Control of healing processes |
WO1997045424A1 (en) | 1996-05-31 | 1997-12-04 | C & C Research Laboratories | Aromatic amidine derivatives useful as selective thrombin inhibitors |
US5985833A (en) | 1996-09-17 | 1999-11-16 | Wisconsin Alumni Research Foundation | Thrombin inhibitor |
ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US5972027A (en) | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US6147109A (en) | 1997-10-14 | 2000-11-14 | The General Hospital Corporation | Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors |
US6280411B1 (en) | 1998-05-18 | 2001-08-28 | Scimed Life Systems, Inc. | Localized delivery of drug agents |
US6335029B1 (en) | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
AU760735B2 (en) | 1998-09-28 | 2003-05-22 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a thrombin inhibitor |
US6168619B1 (en) * | 1998-10-16 | 2001-01-02 | Quanam Medical Corporation | Intravascular stent having a coaxial polymer member and end sleeves |
US6801859B1 (en) * | 1998-12-23 | 2004-10-05 | Rosetta Inpharmatics Llc | Methods of characterizing drug activities using consensus profiles |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US7912651B2 (en) | 2000-03-06 | 2011-03-22 | Bioseek Llc | Function homology screening |
US6763307B2 (en) | 2000-03-06 | 2004-07-13 | Bioseek, Inc. | Patient classification |
US7266458B2 (en) | 2000-03-06 | 2007-09-04 | Bioseek, Inc. | BioMAP analysis |
US20050170015A1 (en) * | 2000-10-31 | 2005-08-04 | Brown Dennis M. | Antiproliferative colchicine compositions and uses thereof |
WO2002066092A2 (en) * | 2001-02-23 | 2002-08-29 | Angiogene Inc. | Drug eluting device for treating vascular diseases |
WO2004045474A1 (en) * | 2002-11-15 | 2004-06-03 | Gmp Cardiac Care, Inc. | Rail stent |
US20050058688A1 (en) * | 2003-02-22 | 2005-03-17 | Lars Boerger | Device for the treatment and prevention of disease, and methods related thereto |
EP1625394A4 (en) | 2003-04-23 | 2008-02-06 | Bioseek Inc | Methods for analysis of biological dataset profiles |
EP1620722A4 (en) | 2003-04-23 | 2008-01-30 | Bioseek Inc | Methods for characterizing signaling pathways and compounds that interact therewith |
JP2007503841A (en) | 2003-09-03 | 2007-03-01 | バイオシーク インコーポレイティッド | Cell-based assay for determining drug action |
US20070155020A1 (en) * | 2005-12-19 | 2007-07-05 | Intel Corporation | Detection of chemical analytes by array of surface enhanced Raman scattering reactions |
-
2007
- 2007-06-04 US US12/302,756 patent/US8697387B2/en active Active
- 2007-06-04 EP EP07809331A patent/EP2023874A4/en not_active Withdrawn
- 2007-06-04 JP JP2009513336A patent/JP2009542583A/en active Pending
- 2007-06-04 WO PCT/US2007/013230 patent/WO2007143211A2/en active Application Filing
-
2014
- 2014-03-18 US US14/218,733 patent/US20140288032A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005093561A1 (en) * | 2004-02-27 | 2005-10-06 | Bioseek, Inc. | Biological dataset profiling of asthma and atopy |
Non-Patent Citations (4)
Title |
---|
BERG E L ET AL: "Biological complexity and drug discovery: a practical systems biology approach Selected Systems Biology papers from the International Conference on Foundations of Systems Biology in Engineering (FOSBE 2005)", 20051209, vol. 152, no. 4, 9 December 2005 (2005-12-09), pages 201 - 206, XP006025688 * |
JASCHKE ET AL: "Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform", CARDIOVASCULAR RESEARCH, OXFORD UNIVERSITY PRESS, vol. 68, no. 3, 1 December 2005 (2005-12-01), pages 483 - 492, XP005151508, ISSN: 0008-6363 * |
MINTZER R J ET AL: "Differential effects of IFN-beta1b on the proliferation of human vascular smooth muscle and endothelial cells.", JOURNAL OF INTERFERON & CYTOKINE RESEARCH : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR INTERFERON AND CYTOKINE RESEARCH NOV 1998, vol. 18, no. 11, November 1998 (1998-11-01), pages 939 - 945, XP008106305, ISSN: 1079-9907 * |
PAN SHIOW-LIN ET AL: "Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats.", BIOCHEMICAL PHARMACOLOGY, vol. 65, no. 11, 1 June 2003 (2003-06-01), pages 1897 - 1905, XP002527931, ISSN: 0006-2952 * |
Also Published As
Publication number | Publication date |
---|---|
EP2023874A2 (en) | 2009-02-18 |
US8697387B2 (en) | 2014-04-15 |
US20140288032A1 (en) | 2014-09-25 |
WO2007143211A3 (en) | 2008-11-06 |
WO2007143211A2 (en) | 2007-12-13 |
JP2009542583A (en) | 2009-12-03 |
US20090304769A1 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2023874A4 (en) | Methods for identifying agents and their use for the prevention of restenosis | |
TWI561237B (en) | Substituted dihydropyrazolones and their use | |
IL196956A0 (en) | Aza-benzofuranyl compounds and methods of use | |
GB0718972D0 (en) | Compounds and methods of making the compounds | |
EP1994181A4 (en) | Identification and use of novopeptides for the treatment of cancer | |
EP1988084A4 (en) | Metal complex and use thereof | |
HK1208000A1 (en) | Thioninium compounds and their use | |
EP2023718A4 (en) | Creatine-ligand compounds and methods of use thereof | |
IL195400A0 (en) | Aldh-2 inhibitors in the treatment of addiction | |
ZA200902189B (en) | Phenylpropionamide compounds and the use thereof | |
EP2135078A4 (en) | Methods for identifying agents and their use for the prevention or stabilization of fibrosis | |
IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
IL194028A0 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
HK1137756A1 (en) | Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4- | |
EP2018163A4 (en) | Imaging agents and methods | |
EP2049141A4 (en) | Treatment for intimal hyperplasia and related conditions | |
PL3216457T3 (en) | Compounds and methods for the prevention or treatment of restenosis | |
GB0611115D0 (en) | Compounds and their use | |
EP2077262A4 (en) | Iminopyridine derivative and use thereof | |
EP2097378A4 (en) | Novel seh inhibitors and their use | |
EP2069371A4 (en) | Organo-arsenoxide compounds and use thereof | |
ZA200900896B (en) | Aza-benzofuranyl compounds and methods of use | |
GB0619611D0 (en) | Compounds and their use | |
GB0608797D0 (en) | Novel agents and the use thereof | |
ZA200901009B (en) | Aza-benzothiophenyl compounds and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081216 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61F 2/06 20060101ALI20090330BHEP Ipc: A61F 2/00 20060101ALI20090330BHEP Ipc: A61F 13/00 20060101AFI20090330BHEP |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/50 20060101ALI20090527BHEP Ipc: A61F 2/06 20060101ALI20090527BHEP Ipc: A61F 2/00 20060101ALI20090527BHEP Ipc: A61F 13/00 20060101AFI20090330BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090605 |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20090930 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100413 |